This might indirectly impact how well medications are handled
This injectable fits the bill The company said it had received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market the drug, following a clinical comparison study
It is administered through a pre-filled syringe rather than a normal injection
("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for glycemic control in adults with type 2 diabetes mellitus (T2DM), making it the world's first approved cAMP-biased GLP-1 receptor agonist
The decision to avoid these products should be individualized based on comprehensive medical history and current health status
Peter Attia, a longevity physician, discusses NAD+ precursors: "While evidence is emerging, NAD+ boosting shows promise for mitochondrial health and longevity, though IV might not be optimalprecursors like NMN could be better."[33][20] On combinations, he cautions on long-term data but notes potential for metabolic disorders